secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024145
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences reports Q3 2022 net loss of $15.9M; initiates global Phase 3 trial for bel-sar in choroidal melanoma
--------------------------------------------------------------------------------

- Net loss $15.9M for Q3 2022 vs $8.8M YoY; cash $111.5M sufficient into 2024.
- Research & development expenses $11.3M (+77% YoY); G&A $4.8M (+92% YoY).
- Global Phase 3 trial for bel-sar in early-stage choroidal melanoma initiated: 3-arm, masked, ~75 patients, adaptive design.
- Positive Phase 2 interim data: tumor growth rate reduction (p=0.0007), 88.9% tumor control rate, favorable safety.
- First patient dosed in Phase 1 for NMIBC; initial data expected in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017022024145/0000950170-22-024145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017022024145/aura-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer